Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Rodrigo CarrascoMaría Cristina RamirezKjersti NesAndrés SchusterRubén AguayoMarcelo MoralesCristobal RamosDaniel HassonCamilo G SotomayorPablo HenriquezIgnacio CortésMarcia ErazoClaudio SalasJuan G GormazPublished in: Trials (2020)
ISRCTN registry, ID: ISRCTN69560410. Registered on 8 June 2016.
Keyphrases
- double blind
- study protocol
- phase iii
- clinical trial
- phase ii
- placebo controlled
- open label
- fatty acid
- oxidative stress
- diabetic rats
- high glucose
- drug delivery
- randomized controlled trial
- left ventricular
- ischemia reperfusion injury
- anti inflammatory
- cancer therapy
- drug induced
- heart failure
- cerebral ischemia
- brain injury